

SUPPLEMENTARY TABLE S2. URINARY GLYCOSAMINOGLYCAN LEVELS IN MUCOPOLYSACCHARIDOSIS VI MICE TREATED WITH EITHER GENE THERAPY OR ENZYME REPLACEMENT THERAPY

Time points (months postinjection)	Urinary GAG levels (% of affected)			
	NR	AF	AAV.hARSB	rhARSB
0.5	31.6±4.3 (n=9)	100.0±11.6 (n=5)	49.4±6.3 (n=5)	80.9*±20.3 (n=5)
1	62.2±6.4 (n=15)	100.0±17.9 (n=11)	49.2±7.6 (n=10)	89.1±37.8 (n=5)
2	42.5±4.4 (n=15)	100.0±11.8 (n=9)	48.6±5.0 (n=12)	37.3±9.1 (n=4)
3	47.1±5.2 (n=14)	100.0±12.7 (n=12)	59.6±5.1 (n=11)	41.5±11.2 (n=5)
4	39.4±4.7 (n=14)	100.0±13.3 (n=8)	52.5±2.8 (n=8)	51.6±9.7 (n=5)
5	41.8±5.0 (n=12)	100.0±9.4 (n=10)	54.9±4.6 (n=11)	57.7±4.4 (n=5)
6	37.7±5.6 (n=13)	100.0±10.4 (n=11)	51.5±7.6 (n=10)	27.4±3.9 (n=5)
7	51.7±5.4 (n=16)	100.0±14.7 (n=11)	49.3±6.2 (n=7)	32.7±6.6 (n=5)
8	39.3±8.3 (n=8)	100.0±9.8 (n=7)	63.2±2.3 (n=2)	30.4±1.3 (n=2)
9	43.6±5.4 (n=10)	100.0±8.5 (n=7)	54.0±10.8 (n=2)	25.8±0.4 (n=2)
10	29.8±5.5 (n=9)	100.0±14.8 (n=7)	44.3±3.5 (n=2)	57.5±6.2 (n=2)
11	35.4±5.3 (n=11)	100.0±17.0 (n=8)	41.6±2.2 (n=2)	25.4±1.7 (n=2)

AF, affected; GAG, glycosaminoglycan; MPS, mucopolysaccharidosis; NR, normal.

Urinary GAGs were measured over time in MPS VI mice treated with either AAV.TBG.hARSB (AAV.hARSB) or rhARSB and in NR and AF controls. The urinary GAG levels were averaged for each time point and the resulting values were then averaged for each group. Results are reported as percentage (%) of AF controls and represented as mean±SE. The number (n) of animals of each group is indicated inside the table. Statistical comparisons were made using the one-way analysis of variance and the Tukey *post hoc* test. The *p*-values vs. AF are ≤0.05, except for the following: NR vs. AF at 1 month postinjection; AAV.hARSB vs. AF at 1, 8, 10, and 11 months postinjection; and rhARSB vs. AF at 0.5, 1, and 10 months postinjection. The *p*-value vs. NR is *≤0.05 and **≤0.01. The exact *p*-values obtained are indicated in the Materials and Methods section.